Aurora Cannabis and Vectura Fertin Pharma have launched a new CBD lozenge, Luo, in Canada. This is the first medical cannabis product from the company to be released in Canada. The lozenge has a unique dissolvable format and is easy to dose. It is available for patients on Aurora's medical cannabis platform, authorized by healthcare professionals.
Cannabidiol (CBD) is a non-psychoactive phytocannabinoid derived from the Cannabis sativa plant, exhibiting a plethora of potential therapeutic benefits, including:
- Analgesic and anti-inflammatory effects
- Anxiolytic and stress-reducing properties
- Sleep aid and insomnia relief
- Anticonvulsant and seizure-control properties
- Anti-inflammatory and antioxidant effects
The product was developed by Vectura Fertin Pharma and manufactured, packaged, and labeled by Cogent, a subsidiary of Vectura Fertin Pharma. It adheres to stringent safety, quality, and regulatory standards. The launch marks the beginning of a strategic collaboration between Aurora Cannabis and Vectura Fertin Pharma.
Through Aurora's patient platform, Cogent will gather patient feedback on the CBD lozenge, which will be used to validate the product proposition and build real-world patient data to inform future products. The two companies will explore opportunities for commercializing other Vectura Fertin Pharma medical cannabis products in Canada.
Key points:
Aurora Cannabis and Vectura Fertin Pharma launched Luo CBD lozenge in Canada.
Unique dissolvable format and easy to dose.
Available on Aurora's medical cannabis platform, authorized by healthcare professionals.
Developed by Vectura Fertin Pharma, manufactured, packaged, and labeled by Cogent.
Adheres to stringent safety, quality, and regulatory standards.
Marks the beginning of a strategic collaboration between Aurora Cannabis and Vectura Fertin Pharma.
Patient feedback will be used to validate the product proposition and build real-world patient data.
(Input from various sources)
(Rehash/Vaishnavi Dalvi)
